The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
August 7, 2023
View Complete Issue         Table of Contents 2019 
Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)
August 7, 2023 (Issue: 1682)
The FDA has approved osimertinib (Tagrisso – AstraZeneca), an oral kinase inhibitor, for adjuvant treatment of non-small cell lung cancer (NSCLC) after tumor resection in adults who have epidermal growth factor receptor (EGFR) exon 19 deletions...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)
Article code: 1682c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.